Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial por Walter Suárez Carmona | Jul 14, 2025
Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society por Walter Suárez Carmona | Jul 4, 2025
Efectos adversos y otros aspectos de los fármacos con efecto incretínico por Walter Suárez Carmona | Jul 3, 2025
